Upgrade to premium to see the full reasoning behind each conviction change.
Sign in to unlockFair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
33.8%/yr
±4.2% · revenue growth to justify current price
FCF-Based Reverse DCF
41.3%/yr
±4.1% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.
Sign in to unlockNaval reactor monopoly is a 40-year cash waterfall — 73% of revenue at 20%+ margins with no competitive threat. Record $7.3B backlog (+50% YoY). TRISO fuel partnership with Kairos positions BWXT as the sole US supplier for the coming SMR fleet. $1.5B NNSA enrichment contract adds another decade-long revenue stream.
Commercial operations (27% of revenue) at only 6.8% margin — improving but still a drag. 43x forward PE is a premium valuation that assumes near-perfect execution on the commercial nuclear ramp. Net debt $1.5B at 3.5x EBITDA limits flexibility if the SMR timeline slips beyond 2030.
NRC regulatory delays beyond 2028, TRISO fuel commoditized by competitor, commercial margins stall below 10%
Updated Mar 11
BWXT joined Burns & McDonnell as sub-contractor for University of Missouri's NextGen MURR research reactor. Stock up 6.3% on the news. TD Securities initiated with Buy and target. Thesis momentum bui...
BWXT added as sub-contractor on U Missouri NextGen MURR research reactor project; TD Securities initiates Buy at PT citing 13.2% annual revenue growth and improving FCF margins. Nuclear momentum buil...
Sole-source naval nuclear propulsion franchise with 70-year moat. 2026 guide: $3.75B revenue, $645-660M EBITDA, 50% backlog growth to $7.3B. EPS growing 11-13% annually. Advanced tech (microreactor, s...
BWXT 2026 guidance confirmed: $3.75B revenue, adjusted EBITDA $645-660M, robust FCF, record backlog. Stock up 111% in 1 year. Federal procurement items tied to BWXT programs continue appearing in Marc...
BWXT confirmed 2026 guidance of .75B revenue and -660M EBITDA, underpinned by record .3B backlog (+50% YoY). Alkeon Capital boosted stake 163%. TD Cowen initiated coverage bullishly. Contract procurem...
BWXT reported Q4 revenue beat and 50% annual backlog surge to .3B. Alkeon Capital acquired 978K additional shares (+163% of position). TD Cowen initiated coverage in March. Federal procurement items c...
Alkeon Capital acquired 978K additional BWXT shares (+163% increase). Follows Q4 revenue beat and 50% YoY backlog surge to .3B. TD Cowen initiated coverage. Strong institutional conviction building ar...
BWXT Q4 earnings beat expectations. Backlog grew 50% YoY to $7.3B — strongest single data point confirming multi-year visibility. TD Cowen initiated coverage. Incremental positive confirmation of 10-K...
FY2025: Revenue +18.3% to $3.2B, backlog +50% to $7.26B, two transformative acquisitions. Margin compression is temporary integration noise. Naval monopoly intact. 0% convertible at $262.51 = manageme...
BWXT opened its Centrifuge Manufacturing Development Facility in Oak Ridge, TN — a milestone toward reestablishing fully domestic uranium enrichment capability. Reinforces defense/energy dual-use thes...
FY2025: Revenue +18.3% to .2B. Backlog surges 50% to .26B. Two major acquisitions (A.O.T, Kinectrics). Issued $1.25B 0% convertible notes. Naval monopoly thesis intact, commercial becoming major growt...
BWXT posted 18% revenue growth to $3.2B and 50% backlog expansion to $7.3B in 2025, driven by naval reactor monopoly (73% revenue, 20%+ margins) and surging commercial nuclear/medical business (63% gr...